Timing of androgen-deprivation therapy in prostate cancer

Duchesne and colleagues1 have again meaningfully contributed to a topic that is important to all patients with cancer: how to capture the value of patient-reported outcomes (PROs) and balance them against the toxic-effects of treatment. [...]we feel that the potentially detrimental effect of androgen deprivation therapy was not fully captured because of the unavoidable restrictions to their otherwise laudable study design, given the realities of time and resource limitations. Editorial assistance was provided by Gail Flores, supported by Tyme, Inc. 1 GM Duchesne, HH Woo, M King, Lancet Oncol, Vol. 18, 2017, 1192-1201 2 G Del Priore, G Sokol, W-T Chen, Phase II trial of SM-88 in non-metastatic biochemical recurrent prostate cancer, Ann Oncol, Vol. 28, Iss. suppl 5, 2017, v269-v294 3 GM Duchesne, HH Woo, JK Bassett, Lancet Oncol, Vol. 17, 2016, 727-737 4 ZS Zumsteg, DE Spratt, PB Romesser, The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy, Eur Urol, Vol. 67, 2015, 1009-1016 5 DM Moreira, LE Howard, KN Sourbeer, Predictors of time to metastasis in castration-resistant prostate cancer, Urology, Vol. 96, 2016, 171-176 6 G Del Priore, S Hoffman, DW Nixon, Proc Am Soc Clin Oncol, Vol. 35, Iss. suppl 15, 2017, TPS 2615.